Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis

In addition to dysregulated JAK/STAT signaling, activation of the AKT/mTOR pathway occurs in myelofibrosis, a myeloproliferative neoplasm with no approved therapies. We conducted a phase 1/2 study with everolimus, an mTOR inhibitor, in 39 high- or intermediate-risk primary or postpolycythemia vera/p...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Guglielmelli, Paola, Barosi, Giovanni, Rambaldi, Alessandro, Marchioli, Roberto, Masciulli, Arianna, Tozzi, Lorenzo, Biamonte, Flavia, Bartalucci, Niccolò, Gattoni, Elisabetta, Lupo, Maria Letizia, Finazzi, Guido, Pancrazzi, Alessandro, Antonioli, Elisabetta, Susini, Maria Chiara, Pieri, Lisa, Malevolti, Elisa, Usala, Emilio, Occhini, Ubaldo, Grossi, Alberto, Caglio, Silvia, Paratore, Simona, Bosi, Alberto, Barbui, Tiziano, Vannucchi, Alessandro M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2011
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3365876/
https://ncbi.nlm.nih.gov/pubmed/21725052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-01-330563
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak